Upon Further Review

Researcher criticizes the many ways opposing viewpoints and dissenting voices are squashed in the field of medicine.

While publication bias has been known to overestimate the efficacy of antidepressant treatments, a new study suggests that research on the use of psychotherapy in depression suffers from a similar bias.

Despite concerns about the risk to benefit ratio, the FDA approved flibanserin (Addyi) to treat low female sexual desire in August. In a new...

A new analysis, published in Lancet Neurology, demonstrates how Biogen is spinning results from two failed trials for a new Alzheimer's drug.

A new article in BMJ Evidence-Based Medicine addresses common misinterpretations of the efficacy research on antidepressants.

A new study, published in the JAMA Psychiatry, investigates the effect of stimulant ‘ADHD’ drugs on the brains of children and young adults. The...

The Scientific American reports on a new analysis of antidepressant trials revealing that the vast majority of meta-analyses have industry links and suppress negative results.

Review of a new mixed depression guideline reveals financial bias of guideline developers and lack of evidence supporting recommendations for prescribing of antipsychotics.

Jürgen Margraf and Silvia Schneider, both well-known psychologists at the University of Bochum in Germany, claim that psychotropic drugs are no solution to mental...

A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.

A new study analyzing over 21,000 participants found that differences in activation of brain regions in different psychological “disorders” may have been overestimated, and confirms that there is still no brain scan capable of diagnosing a mental health concern.

A new study, published online by the Open Science Foundation, suggests that questionable research practices (QRPs) are prevalent in the fields of ecology and evolution.

A new study reports that the supplement EPA improved ADHD symptoms but a closer look calls these results into question.

Reanalysis of the original primary outcome measure in the STAR*D study suggests STAR*D findings inflate improvement on antidepressant medication and exclusion criteria in conventional clinical trials results in overestimation of antidepressant efficacy.

Dr. Madhukar Trivedi and colleagues find that the SSRI sertraline does not reduce depressive symptoms any more than placebo in people with Chronic Kidney Disease.

Surveyed doctors overestimate pharmacological effects of antidepressants and underestimate placebo effects.

An article published this month in the journal BMC Psychiatry suggests that there is a lack of efficacy for SSRIs and that they significantly increase the risk of serious side effects.

An international group of researchers, including several with financial ties to manufacturers of antidepressants, explore possible explanations for why long-term users of antidepressants become chronically depressed.

The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.

In a new study, researchers examined 29 popular introduction to psychology textbooks and found that almost 80% included misinformation about intelligence.

Earlier this year, the US Preventative Services Task Force (USPSTF) came out with the controversial recommendation that all adolescent and adult patients undergo depression...

In the September issue of The Journal of the American Medical Association (JAMA) three FDA advisory committee members describe the convergence of factors that made the committee’s recommendation to approve flibanserin especially challenging and politically charged.

From The British Psychological Society: A recent meta-analysis has raised concerns about the validity of previous studies on the effectiveness of psychotherapy, calling their methodology and...

Researchers from the City College of New York and Columbia University published a study this month testing the hypothesis that people diagnosed with schizophrenia treated long-term with antipsychotic drugs have worse outcomes than patients with no exposure to these drugs. They concluded that there is not a sufficient evidence base for the standard practice of long-term use of antipsychotic medications.

For MinnPost, Susan Perry discusses that the pharmaceutical industry played in the creation of the ‘mental disorder’ known as premenstrual dysphoric disorder or PMDD....